Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in <scp>CHIMES</scp> : A Single‐Arm Clinical Trial

Lilyana Amezcua, Anthony T. Reder, Evanthia Bernitsas, Nancy L. Monson, Timothy Vartanian, Gregory F. Wu, Mansoor Saleh, Annette Okai, Ahmed Z. Obeidat, Dilraj Sokhi, Rikisha Parekh, Jinglan Pei, Christopher Harp, David Clayton, Ibraheem Abioye, Mitzi J. Williams, Unknown

Open source

DOI: 10.1002/ana.78290
Published: 2026-07-30
Container: Annals of Neurology
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ana.78290,
  title = {Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in
                    <scp>CHIMES</scp>
                    : A Single‐Arm Clinical Trial},
  author = {Lilyana Amezcua and Anthony T. Reder and Evanthia Bernitsas and Nancy L. Monson and Timothy Vartanian and Gregory F. Wu and Mansoor Saleh and Annette Okai and Ahmed Z. Obeidat and Dilraj Sokhi and Rikisha Parekh and Jinglan Pei and Christopher Harp and David Clayton and Ibraheem Abioye and Mitzi J. Williams and Unknown},
  year = {2026},
  journal = {Annals of Neurology},
  doi = {10.1002/ana.78290},
  url = {https://doi.org/10.1002/ana.78290}
}

RIS

TY  - JOUR
TI  - Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in
                    <scp>CHIMES</scp>
                    : A Single‐Arm Clinical Trial
AU  - Lilyana Amezcua
AU  - Anthony T. Reder
AU  - Evanthia Bernitsas
AU  - Nancy L. Monson
AU  - Timothy Vartanian
AU  - Gregory F. Wu
AU  - Mansoor Saleh
AU  - Annette Okai
AU  - Ahmed Z. Obeidat
AU  - Dilraj Sokhi
AU  - Rikisha Parekh
AU  - Jinglan Pei
AU  - Christopher Harp
AU  - David Clayton
AU  - Ibraheem Abioye
AU  - Mitzi J. Williams
AU  - Unknown
PY  - 2026
JO  - Annals of Neurology
DO  - 10.1002/ana.78290
UR  - https://doi.org/10.1002/ana.78290
ER  -

APA

Amezcua, L., Reder, A. T., Bernitsas, E., Monson, N. L., Vartanian, T., Wu, G. F., Saleh, M., Okai, A., Obeidat, A. Z., Sokhi, D., Parekh, R., Pei, J., Harp, C., Clayton, D., Abioye, I., Williams, M. J., & Unknown (2026). Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in <scp>CHIMES</scp> : A Single‐Arm Clinical Trial. Annals of Neurology. https://doi.org/10.1002/ana.78290

Source records

crossref · retrieved 2026-09-24T19:46:05.475Z